JP2905911B2 - Agent for suppressing or increasing the number of helper T cells in AIDS - Google Patents
Agent for suppressing or increasing the number of helper T cells in AIDSInfo
- Publication number
- JP2905911B2 JP2905911B2 JP5218908A JP21890893A JP2905911B2 JP 2905911 B2 JP2905911 B2 JP 2905911B2 JP 5218908 A JP5218908 A JP 5218908A JP 21890893 A JP21890893 A JP 21890893A JP 2905911 B2 JP2905911 B2 JP 2905911B2
- Authority
- JP
- Japan
- Prior art keywords
- helper
- cells
- aids
- maitake
- suppressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明はＡＩＤＳ（エイズ）にお
けるヘルパーＴ細胞（ＣＤ４陽性リンパ球〔以下ＣＤ４
と表す〕）数の減少抑制若しくは増加剤に関するもので
ある。This invention relates to AIDS (AIDS) .
Helper T cells (CD4-positive lymphocytes [hereinafter CD4
]) This relates to an agent for suppressing or increasing the decrease in the number .
【０００２】[0002]
【従来の技術及び発明が解決しようとする課題】ＡＩＤ
Ｓは、後天性免疫不全症候群と云われるように免疫が低
下するものである。即ち、ヘルパーＴ細胞がＨＩＶのタ
ーゲット細胞である。このＡＩＤＳによる免疫の低下を
防止するため、本発明者等は、マイタケが有する免疫強
化作用に着目し、ＨＩＶの感染によって認められるヘル
パーＴ細胞数の減少を抑制若しくは増加させると共に、
関連症状の改善を行わせることを目的として種々実験を
繰り返した結果、本発明を完成した。2. Description of the Related Art AID
S is one in which immunity is reduced, which is called acquired immunodeficiency syndrome. That is, helper T cells are target cells for HIV. In order to prevent the reduction of immunity due to AIDS, the present inventors focused on the immunopotentiating effect of maitake, and suppressed or increased the decrease in the number of helper T cells observed by HIV infection,
As a result of repeating various experiments for the purpose of improving related symptoms, the present invention was completed.
【０００３】この様なマイタケが有する免疫強化作用を
用いてＡＩＤＳ症を改善する方法はいまだ行われておら
ず、この方法が我国において最初のものであり、世界で
も例がない。[0003] A method for improving AIDS disease by using the immunopotentiating action of maitake has not yet been performed, and this method is the first in Japan and has no examples in the world.
【０００４】[0004]
【課題を解決するための手段】本発明の要旨を説明す
る。The gist of the present invention will be described.
【０００５】ＡＩＤＳにおけるヘルパーＴ細胞数の減少
抑制若しくは増加剤であって、マイタケの子実体若しく
は培養菌糸体を乾燥し、該乾燥物を粉末化して成る、投
与量が成人１日当たり３乃至１０ｇであることを特徴と
するＡＩＤＳにおけるヘルパーＴ細胞数の減少抑制若し
くは増加剤に係るものである。[0005] Reduction of helper T cell numbers in AIDS
It is a suppressant or an enhancer, and the fruit body of Maitake is young
Is a method of drying cultured mycelium and pulverizing the dried product.
The dosage is 3 to 10 g per adult per day.
Suppression of helper T cell count in AIDS
Or an increaser .
【０００６】ＡＩＤＳにおけるヘルパーＴ細胞数の減少
抑制若しくは増加剤であって、マイタケの子実体若しく
は培養菌糸体を乾燥し、該乾燥物を粉末化して成る、投
与量が成人１日当たり３ｇであることを特徴とするＡＩ
ＤＳにおけるヘルパーＴ細胞数の減少抑制若しくは増加
剤に係るものである。[0006] Reduced number of helper T cells in AIDS
It is a suppressant or an enhancer, and the fruit body of Maitake is young
Is a method of drying cultured mycelium and pulverizing the dried product.
AI characterized in that the dosage is 3 g per adult per day
Suppression or increase of helper T cell count in DS
Pertaining to agents .
【０００７】[0007]
【０００８】[0008]
【０００９】[0009]
【作用】マイタケ中のグルカンがヘルパーＴ細胞の減少
を抑制若しくは増加させる。The glucan in maitake suppresses or increases the decrease in helper T cells.
【００１０】[0010]
【実施例】マイタケ（チョレイマイタケや白マイタケな
どGrifola属に属するものはすべて含まれる。）の子実
体（人口栽培および天然物のいずれでもよい。）若しく
は培養菌糸のいずれでもよいが、これらの乾燥物から得
た粉末を錠剤状にしたものまたは該乾燥物の熱水可溶物
をドリンク剤状にしたものを用いる。EXAMPLES The fruit body of maitake (including all those belonging to the genus Grifola, such as Choreimaitake and white maitake) may be any of artificially cultivated and natural products or cultured mycelium. The powder obtained from the dried product is made into a tablet, or the hot-water-soluble material of the dried product is made into a drink.
【００１１】マイタケの乾燥粉末を低温下（４°Ｃ〜８
０°Ｃ）で打錠する。この時、各種のビタミンをマイタ
ケ特有の香りを緩和すると共に該粉末の酸化を防止する
ため、粉末１００ｍｇ当たり１〜２０ｍｇの割合で混合
する。[0011] The dry powder of Grifola low temperature (4 ° C~8
Tablet at 0 ° C). At this time, various vitamins are mixed at a ratio of 1 to 20 mg per 100 mg of the powder in order to alleviate the fragrance peculiar to Maitake and prevent oxidation of the powder.
【００１２】打錠せず、この混和物をカプセルにつめた
り、或いは、そのまま粉末状のものとしたりしても良
い。This tablet may be filled in a capsule without compression, or may be made into a powder form as it is.
【００１３】尚、ビタミンを混和することは必ずしも必
要とするものではなく、無添加でも良い。It should be noted that it is not always necessary to mix vitamins, and they may not be added.
【００１４】この粉末は１日当たり３ｇ〜１０ｇ経口投
与する。This powder is orally administered in an amount of 3 g to 10 g per day.
【００１５】また、生マイタケの子実体１ｋｇ若しくは
生マイタケの子実体の乾燥物２００ｇに、水を２リット
ル若しくは８００ｍｌを加え、９０°Ｃ〜１４０°Ｃの
加熱処理を行う。得られた抽出液そのまま、または抽出
液中に含まれる高分子多糖体をエキスとして経口投与に
用いる。Further, 2 liters or 800 ml of water is added to 1 kg of raw maitake fruit body or 200 g of dried raw maitake fruit body, and a heat treatment at 90 ° C. to 140 ° C. is performed. The obtained extract is used as it is, or the high molecular polysaccharide contained in the extract is used for oral administration as an extract.
【００１６】尚、この多糖物は注射によって投与しても
良い。更に、このエキスを乾固し、乳糖などに混じ、錠
剤またはカプセルにつめて経口投与しても良い。The polysaccharide may be administered by injection. Further, the extract may be dried, mixed with lactose or the like, and packed in tablets or capsules for oral administration.
【００１７】このエキスは糖量にして１日当たり１０ｍ
ｇ〜２００ｍｇ経口投与する。This extract has a sugar content of 10 m / day
g-200 mg orally.
【００１８】ＡＩＤＳ患者に、前記マイタケの粉末を１
日３ｇ経口投与し、２カ月後のヘルパーＴ細胞（ＣＤ
４）の数を調べたところ、増加または減少が抑えられる
ことが認められた。その結果の一部は次の表１である。For AIDS patients, the maitake powder was
3 g / day orally and 2 months later, helper T cells (CD
When the number of 4) was examined, it was found that the increase or decrease was suppressed. Some of the results are shown in Table 1 below.
【表１】 表２に、この時のヘルパーＴ細胞（ＣＤ４）数対サプレ
ッサーＴ細胞（ＣＤ８）数の比率の一部を示す。[Table 1] Table 2 shows a part of the ratio of the number of helper T cells (CD4) to the number of suppressor T cells (CD8) at this time.
【表２】 一般に健常者ではヘルパーＴ細胞（ＣＤ４）／サプレッ
サーＴ細胞（ＣＤ８）の比率は約２であるが、この表２
にも示すようにＡＩＤＳ患者ではヘルパーＴ細胞（ＣＤ
４）の数が減少することにより、その比率も非常に小さ
くなっている。しかし、前記マイタケの粉末の投与によ
り、その比率が増加することが認められた。[Table 2] In general, the ratio of helper T cells (CD4) / suppressor T cells (CD8) is about 2 in healthy subjects.
As shown also in AIDS patients, helper T cells (CD
As the number of items 4) decreases, the ratio becomes very small. However, it was found that the administration of the maitake powder increased the ratio.
【００１９】この結果は、ＨＩＶ感染によって生ずるヘ
ルパーＴ細胞（ＣＤ４）の減少を、マイタケがその免疫
力の増強または回復作用によって抑制することを示すも
のである。These results indicate that Maitake mushroom suppresses the decrease in helper T cells (CD4) caused by HIV infection by enhancing or restoring its immunity.
【００２０】これは、現在、治療に用いられているＡＺ
ＴやＤＤＩがＨＩＶの増殖に関する逆転写酵素の作用な
どを直接的に阻害し、症状改善或いは回復を行わせるも
のとは全く異なり、免疫力の改善、回復を行わせて治療
を行うというものである。This is because AZ is currently used for treatment.
T and DDI directly inhibit the action of reverse transcriptase on HIV growth, etc., and are completely different from those that improve or relieve symptoms. is there.
【００２１】このような事実に基づいてＡＩＤＳ症を軽
減しようという試みは我国においてのみならず世界的に
も初めてのものである。An attempt to reduce AIDS based on such facts is the first in Japan as well as in the world.
【００２２】その結果ＨＩＶのターゲットであるヘルパ
ーＴ細胞（ＣＤ４）の回復のみならず、表３に示すよう
なＡＩＤＳ関連症候をも軽減し得た。As a result, not only recovery of helper T cells (CD4) , which is a target of HIV, but also AIDS-related symptoms as shown in Table 3 could be reduced.
【表３】 以上の臨床試験結果は、マイタケの粉末を経口投与する
と、ＨＩＶ陽性患者（ＡＩＤＳ患者及びＡＩＤＳキャリ
ヤーを含む。）の免疫力の回復が認められ、その結果と
してＨＩＶ感染にともなうＡＩＤＳ関連症候症状が軽減
されることを示すものである。[Table 3] Clinical test results described above, when administered orally powder maitake, observed recovery of immunity HIV-positive patients (. Including AIDS patients and AIDS carriers), AIDS-related symptoms symptoms associated with HIV infection as a result It shows that it is reduced.
【００２３】我国においてのみならず、世界的にもこの
ようなマイタケの製剤を用いたＡＩＤＳに対する一連の
臨床試験例はなく、これが初めてであり、かつ有効との
判定から、本発明は有意義なものと考える。尚、前記マ
イタケのエキス投与でも、同様の臨床試験結果が得られ
ている。[0023] Not only in Japan, worldwide is also not a series of clinical Test Example for AIDS using formulations such maitake, this is the first time, and from the determination of the active, the present invention is meaningful Think of things. Also in extract administration of the maitake, similar clinical test results have been obtained.
【００２４】[0024]
【発明の効果】本発明は上述のようにしたから、本発明
に係る物質を使用することで、ＨＩＶ陽性患者の免疫力
の回復が達成され、その結果としてＨＩＶ感染に伴うＡ
ＩＤＳ関連症候症状の軽減も可能となる。As described above, the present invention has been described above. Thus, by using the substance according to the present invention, the immunity of HIV-positive patients can be restored, and as a result, A associated with HIV infection can be recovered.
It is also possible to reduce IDS-related symptoms and symptoms.
フロントページの続き (56)参考文献 特開 平４−66536（ＪＰ，Ａ) 特開 平２−286623（ＪＰ，Ａ) 特開 平２−134325（ＪＰ，Ａ) 特開 平４−308531（ＪＰ，Ａ) 特開 平１−312980（ＪＰ，Ａ) 特開 平２−211848（ＪＰ，Ａ) 特開 平５−336918（ＪＰ，Ａ) 難波宏彰，「マイタケの不思議パワ ー」、ＫＫベストセラーズ、1992年10月 ５日初版発行、第138〜141頁 川合正充，「きのこの利用」、築地書 館株式会社、1988年12月15日初版発行、 第83〜87頁 水野卓，「キノコの化学・生化学」株 式会社学会出版センター、1992年１月15 日、第237〜244頁Continuation of the front page (56) References JP-A-4-66536 (JP, A) JP-A-2-286623 (JP, A) JP-A-2-134325 (JP, A) JP-A-4-308531 (JP) JP-A-1-312980 (JP, A) JP-A-2-211848 (JP, A) JP-A-5-336918 (JP, A) Hiroaki Namba, "Mysterious Power of Maitake", KK Bestsellers , October 5, 1992, First Edition, pp. 138-141, Masamitsu Kawai, "Use of Mushrooms", Tsukiji Shokan Co., Ltd., First Edition, December 15, 1988, pp. 83-87, Taku Mizuno, "Mushroom Chemistry and Biochemistry, Inc. Publishing Center, January 15, 1992, pp. 237-244
Claims (2)
少抑制若しくは増加剤であって、マイタケの子実体若し
くは培養菌糸体を乾燥し、該乾燥物を粉末化して成る、
投与量が成人１日当たり３乃至１０ｇであることを特徴
とするＡＩＤＳにおけるヘルパーＴ細胞数の減少抑制若
しくは増加剤。1. An agent for suppressing or increasing the number of helper T cells in AIDS, comprising drying a fruit body or a cultured mycelium of Maitake, and powdering the dried product.
An agent for suppressing or increasing the number of helper T cells in AIDS, wherein the dose is 3 to 10 g per adult per day.
少抑制若しくは増加剤であって、マイタケの子実体若し
くは培養菌糸体を乾燥し、該乾燥物を粉末化して成る、
投与量が成人１日当たり３ｇであることを特徴とするＡ
ＩＤＳにおけるヘルパーＴ細胞数の減少抑制若しくは増
加剤。2. An agent for suppressing or increasing the number of helper T cells in AIDS, comprising drying a fruit body or a cultured mycelium of Maitake and powdering the dried product.
A characterized in that the dosage is 3 g per adult per day
An agent for suppressing or increasing the number of helper T cells in IDS.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5218908A JP2905911B2 (en) | 1993-09-02 | 1993-09-02 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5218908A JP2905911B2 (en) | 1993-09-02 | 1993-09-02 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29334698A Division JP3195916B2 (en) | 1993-09-02 | 1998-10-15 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0769913A JPH0769913A (en) | 1995-03-14 |
| JP2905911B2 true JP2905911B2 (en) | 1999-06-14 |
Family
ID=16727205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5218908A Expired - Lifetime JP2905911B2 (en) | 1993-09-02 | 1993-09-02 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2905911B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2859843B2 (en) * | 1996-03-08 | 1999-02-24 | 株式会社雪国まいたけ | Antitumor substance extracted from Maitake |
| JP4842507B2 (en) * | 2003-11-19 | 2011-12-21 | 株式会社雪国まいたけ | Anti-influenza virus activator |
| JP2008106018A (en) | 2006-10-27 | 2008-05-08 | Yukiguni Maitake Co Ltd | Substance having anti-influenza virus activity derived from grifola frondosa and its manufacturing method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01312980A (en) * | 1988-06-10 | 1989-12-18 | Noda Shiyokukin Kogyo Kk | Production of healthy food |
| JPH02211848A (en) * | 1989-02-10 | 1990-08-23 | Iwade Kingaku Kenkyusho:Kk | Functional food containing protein polysaccharide component of agaricus blazei |
-
1993
- 1993-09-02 JP JP5218908A patent/JP2905911B2/en not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| 川合正充，「きのこの利用」、築地書館株式会社、１９８８年１２月１５日初版発行、第８３〜８７頁 |
| 水野卓，「キノコの化学・生化学」株式会社学会出版センター、１９９２年１月１５日、第２３７〜２４４頁 |
| 難波宏彰，「マイタケの不思議パワー」、ＫＫベストセラーズ、１９９２年１０月５日初版発行、第１３８〜１４１頁 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0769913A (en) | 1995-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6468542B2 (en) | Germination activated Ganoderma lucidum spores and method for producing the same | |
| JP2905911B2 (en) | Agent for suppressing or increasing the number of helper T cells in AIDS | |
| US2935448A (en) | Phosphatide therapeutic composition and method of treatment therewith | |
| US6746675B2 (en) | Physiologically active compositions based upon active ingredients of Basidiomycotina and Araliaceae | |
| JP3195916B2 (en) | Agent for suppressing or increasing the number of helper T cells in AIDS | |
| US6893641B2 (en) | Ganoderma lucidum spores for treatment of autoimmune diseases | |
| US8609160B2 (en) | Composition and method of treating lipid encapsulated virus infections | |
| JPH02134325A (en) | Remedy for aids and production thereof | |
| KR101266527B1 (en) | Composition for inhibition of trasplant rejection containing the cordyceps mycellia extract as an active ingredient | |
| GB2359562A (en) | T cell immunoactivity potentiators containing shiit ake mushroom hypha extract | |
| JPH0925237A (en) | Therapeutic agent for viral disease containing cordyceps sinensis sacc. | |
| JPH06199674A (en) | Medicine related to treatment and prevention for opportunistic infectious disease | |
| JPH02503314A (en) | Treatment agent for human dyslipidemia | |
| Duke | Effect of trichlorophone against West African forest strain of Onchocerca volvulus | |
| CA2168263A1 (en) | Pharmaceutical compositions | |
| EP0631785A1 (en) | Mineral ion solution, anti-human immunodeficiency virus agent, and aids-treating agent | |
| WO2008064411A1 (en) | Nutritional supplement | |
| JPH07215852A (en) | Immunosuppressant | |
| JP2001163797A (en) | Hepatitis protective agent | |
| JPS63208533A (en) | Crude drug raw material having medicinal effect on aids | |
| JPS60192554A (en) | Method of removing bitterness from essence | |
| EP0765662A1 (en) | Hiv growth inhibitory composition | |
| JPH06128288A (en) | Polypeptide and medicinal composition for treatment of viral infection containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110402 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120402 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120402 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130402 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140402 Year of fee payment: 15 |